Silence Therapeutics PLC Sponsored ADR (NASDAQ:SLN) Stock Has Average Price Target of $24.00

Key Points

• Analyst sentiment is mixed but leans cautious: Seven firms give Silence Therapeutics an average “Hold” rating, with one sell, four holds and two buys. The average 12-month price target is $24, though several analysts recently downgraded the stock.
• The company reported a quarterly loss of $0.24 per share, missing the consensus estimate of a $0.11 loss; analysts expect a full-year loss of $0.82 per share.
• Shares traded at $19.83, close to their 12-month high of $19.86, while institutional investors own 98.73% of the stock.

Shares of Silence Therapeutics PLC Sponsored ADR (NASDAQ:SLN - Get Free Report) have been assigned an average rating of "Hold" from the seven research firms that are currently covering the stock, MarketBeat reports. One investment analyst has rated the stock with a sell recommendation, four have given a hold recommendation and two have issued a buy recommendation on the company. The average twelve-month target price among analysts that have issued a report on the stock in the last year is $24.00.

SLN has been the topic of a number of recent analyst reports. Weiss Ratings reaffirmed a "sell (d-)" rating on shares of Silence Therapeutics in a research report on Thursday, October 15th. William Blair cut shares of Silence Therapeutics from an "outperform" rating to a "hold" rating in a research report on Monday, October 19th. HC Wainwright cut shares of Silence Therapeutics from a "buy" rating to a "neutral" rating and reduced their price target for the company from $75.00 to $20.00 in a research report on Wednesday, October 21st. Jefferies Financial Group downgraded shares of Silence Therapeutics from a "buy" rating to a "hold" rating and set a $20.00 price objective for the company. in a research note on Monday, October 19th. Finally, Chardan Capital lowered Silence Therapeutics from a "strong-buy" rating to a "hold" rating in a report on Wednesday, October 21st.

Institutional Investors Weigh In On Silence Therapeutics

A number of institutional investors and hedge funds have recently added to or reduced their stakes in SLN. 5AM Venture Management LLC acquired a new stake in shares of Silence Therapeutics in the second quarter valued at approximately $5,228,676. Aberdeen Group plc acquired a new position in shares of Silence Therapeutics in the 3rd quarter valued at $2,207,000. ADAR1 Capital Management LLC raised its position in Silence Therapeutics by 628.2% in the 1st quarter. ADAR1 Capital Management LLC now owns 172,157 shares of the company's stock valued at $907,000 after purchasing an additional 148,514 shares during the last quarter. Seven Fleet Capital Management LP raised its position in Silence Therapeutics by 6.2% in the 1st quarter. Seven Fleet Capital Management LP now owns 156,759 shares of the company's stock valued at $826,000 after purchasing an additional 9,159 shares during the last quarter. Finally, Squarepoint Ops LLC boosted its stake in Silence Therapeutics by 29.6% during the 2nd quarter. Squarepoint Ops LLC now owns 115,918 shares of the company's stock worth $1,273,000 after purchasing an additional 26,449 shares during the period. Hedge funds and other institutional investors own 98.73% of the company's stock.

Silence Therapeutics Price Performance

Shares of NASDAQ SLN traded up $0.03 during midday trading on Friday, hitting $19.83. 586,512 shares of the company's stock were exchanged, compared to its average volume of 5,721,501. The firm's fifty day simple moving average is $14.66 and its 200-day simple moving average is $9.75. The company has a market cap of $1.23 billion, a PE ratio of -18.53 and a beta of 1.34. Silence Therapeutics has a twelve month low of $4.19 and a twelve month high of $19.86.

Silence Therapeutics (NASDAQ:SLN - Get Free Report) last announced its quarterly earnings results on Thursday, November 12th. The company reported ($0.24) EPS for the quarter, missing the consensus estimate of ($0.11) by ($0.13). Silence Therapeutics had a negative net margin of 8,943.86% and a negative return on equity of 102.72%. Equities analysts anticipate that Silence Therapeutics will post -0.82 EPS for the current fiscal year.

Silence Therapeutics Company Profile

Silence Therapeutics is a biotechnology company developing medicines based on RNA interference (RNAi), a biological process that can reduce production of specific disease-related proteins. Its proprietary mRNAi GOLD platform is designed to create small interfering RNA (siRNA) medicines, including treatments that target genes expressed in the liver. The company's research and development programs have included zerlasiran, which targets lipoprotein(a), a risk factor for cardiovascular disease, and divesiran, investigated for blood disorders.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.